title: Failure of sputum eosinophilia after eotaxin inhalation in asthma.
abstract: BACKGROUND
  Eotaxin is a chemokine specific for eosinophils and may play an important role in eosinophil recruitment in asthma. The effects of eotaxin inhalation on sputum and blood eosinophils, exhaled nitric oxide (NO), and bronchial responsiveness were determined.
  
  
  METHODS
  Eotaxin was administered by nebulisation to asthma patients in three studies: (1) an open dose finding study with eotaxin (5, 10 and 20 microg) to two asthmatic subjects; (2) a randomised placebo controlled study with 20 microg eotaxin to five asthmatic subjects and five normal volunteers; and (3) a randomised placebo controlled study with 40 microg eotaxin to nine asthmatics. Forced expiratory volume in 1 second (FEV(1)), exhaled NO, and blood eosinophils were measured before and hourly for 5 hours after nebulisation and at 24 and 72 hours. Methacholine bronchial challenge and sputum induction were performed before and at 5, 24, and 72 hours after nebulisation.
  
  
  RESULTS
  In the two placebo controlled studies there was no change in sputum eosinophil count and sputum eosinophilic cationic protein concentration after eotaxin inhalation compared with placebo. FEV(1), exhaled NO, and methacholine PC(20) did not change. However, high dose eotaxin (40 microg) induced an increase in sputum neutrophil count compared with placebo (p<0.05).
  
  
  CONCLUSIONS
  Inhaled eotaxin up to 40 microg induced no changes in sputum eosinophil count but at 40 microg it increased the sputum neutrophil count. The significance of this finding is unknown.
authors.affiliation: Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK.
authors.forename: D
authors.initials: D
authors.lastname: Bumbacea
authors.forename: J
authors.initials: J
authors.lastname: Scheerens
authors.forename: B S
authors.initials: BS
authors.lastname: Mann
authors.forename: R G
authors.initials: RG
authors.lastname: Stirling
authors.forename: K F
authors.initials: KF
authors.lastname: Chung
mesh_terms: D000280:Administration, Inhalation; D001249:Asthma / Q000473:pathology* / Q000503:physiopathology; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004802:Eosinophilia / Q000473:pathology* / Q000503:physiopathology; D004804:Eosinophils; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D013183:Sputum / Q000166:cytology*
chemical_list: C515456:CCL11 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC